PI3K and AKT Inhibitors Linked to Hyperglycemia in HR+ Breast Cancer Patients

Researchers are observing that PI3K and AKT inhibitors can lead to hyperglycemia in individuals with hormone receptor-positive (HR+) breast cancer. This adverse effect has emerged as a common and noteworthy issue during treatment. Specifically, studies indicate that patients with HR+ breast cancer who are treated with PI3K and AKT inhibitors frequently experience hyperglycemia. Hyperglycemia, or high blood sugar, requires careful monitoring and management due to its potential impact on overall health and treatment outcomes. The prevalence and significance of this side effect highlight the importance of understanding and addressing metabolic changes associated with these targeted therapies.

Newsflash | Powered by GeneOnline AI
Date: April 29, 2025

Related posts:

Hidden transmission of avian influenza virus H5N1 found in Texas dairy cattle Specialty Pharmacies Use AI to Analyze Data and Tailor Clinical Programs Aetna to Exit ACA Individual Marketplaces Again in 2026 Autism Screening Cancellations Rise Amid Fears of Federal List Placement

Author

Mark Chiang

紐約 NYU Computer Science 碩士 紐澤西 UMDNJ Biomedical Informatics 博士 中研院博士後 台灣大學博士後